Establishment and Validation of LC-MS/MS Technique for Pafolacianine Quantification in Rat Plasma, with Application to Pharmacokinetic Assessment

被引:0
作者
Pilli, Sandhya [1 ]
Kalakonda, Sri Nataraj [2 ]
Rajendran, Vijayalakshmi [3 ]
机构
[1] Andhra Univ, Sri Vishnu Coll Pharm, Dept Pharmaceut Anal, Bhimavaram 534202, Andhra Pradesh, India
[2] Sri Vishnu Coll Pharm, Dept Pharmaceut Anal, Bhimavaram, Andhra Pradesh, India
[3] GIET Sch Pharm, Dept Pharmaceut Anal, Rajahmundry, Andhra Pradesh, India
关键词
Pafolacianine; Phenylalanine; Pharmacokinetics; Bio-analytical; Rat plasma; LC-MS/; MS;
D O I
10.5530/ijper.58.4s.119
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
Background: Establishing and validating a sensitive and accurate LC-MS method for quantifying pafolacianine in rat plasma was the primary objective of this study. Phenylalanine was used as the internal standard, and the validation procedure adhered to the protocols specified by the Food and Drug Administration of the United States. Materials and Methods: This article presents an overview of the bioanalytical LC-MS method, utilizing an Inertsil ODS column (150 mm x 4.6 mm, 3.5 mu m) and an organic mobile phase comprising acetonitrile and 0.1% formic acid buffer in a ratio of 40:60. Results: The calibration curve for pafolacianine exhibited a linearity range of 5-100 ng/mL (r2=0.9999). Liquid-liquid extraction was employed to recover pafolacianine from rat plasma, resulting in recovery percentages of 100%, 99.7%, and 99.8% at three different concentration levels. Pafolacianine remained stable during storage under various conditions (three freeze-thaw cycles, benchtop, autosampler, short-term, and long-term storage). Pharmacokinetic analysis yielded key parameters, including a half-life of 9.6 m and a time to reach a maximum concentration of 5 m. Pafolacianine and phenylalanine were identified using proton adducts in the LC-MS analysis at m/z 1326.3/574.6 and 166.08/144.8, respectively, by employing positive mode multiple reaction monitoring. Conclusion: This comprehensive evaluation demonstrates that the method meets stringent criteria for system specificity, linearity, and accuracy, all well within the predefined acceptance limits. Its adaptability for the precise determination of pafolacianine positions it as an invaluable tool in the field of bioanalysis, expanding its clinical utility.
引用
收藏
页码:S1224 / S1233
页数:10
相关论文
共 10 条
[1]  
[Anonymous], 2021, Approves Imaging Drug to Help Identify Lung Lesions During SurgeryFDA
[2]  
FDA Pregnancy Outcomes Working Group, 2001, Guidance for Industry: bioanalytical method validation
[3]  
Guidance for Industry, 2001, Bioanalytical Method Validation
[4]  
Langman LJ., 2012, LC-MS in drug analysis: methods and protocols
[5]   Ovarian Cancer: Treatment and Resistance to Pharmacotherapy [J].
Lukanovic, David ;
Kobal, Borut ;
Cerne, Katarina .
REPRODUCTIVE MEDICINE, 2022, 3 (02) :127-140
[6]  
Niessen WMA, 1999, Liquid chromatography-mass spectrometry, V79, P337
[7]  
Pandey Saurabh, 2010, Pharm Methods, V1, P14, DOI 10.4103/2229-4708.72223
[8]   In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications [J].
Refaat, Ahmed ;
Yap, May Lin ;
Pietersz, Geoffrey ;
Walsh, Aidan Patrick Garing ;
Zeller, Johannes ;
del Rosal, Blanca ;
Wang, Xiaowei ;
Peter, Karlheinz .
JOURNAL OF NANOBIOTECHNOLOGY, 2022, 20 (01)
[9]   A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006) [J].
Tanyi, Janos L. ;
Randall, Leslie M. ;
Chambers, Setsuko K. ;
Butler, Kristina A. ;
Winer, Ira S. ;
Langstraat, Carrie L. ;
Han, Ernest S. S. ;
Vahrmeijer, Alexander L. ;
Chon, Hye Sook ;
Morgan, Mark A. ;
Powell, Matthew A. ;
Tseng, Jill H. ;
Lopez, Alexis S. ;
Wenham, Robert M. .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) :276-+
[10]  
Zaryab G, 2023, Annals Transitional Med, V11, P23